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Serum galactose-deficient immunoglobulin A1 (Gd-IgA1) is
an inherited risk factor for adult IgA nephropathy (IgAN). In
this paper, we determined the heritability of serum Gd-IgA1
levels in children with IgAN and Henoch–Scho¨nlein purpura
nephritis (HSPN), two disorders with clinical phenotypes
sharing common pathogenic mechanisms. Serum Gd-IgA1
concentrations were quantified using a Helix aspersa-lectin-
based enzyme-linked immunosorbent assay. As a group,
34 children with either disorder (20 with HSPN and 14 with
IgAN) had significantly higher Gd-IgA1 levels compared with
51 age- and ethnicity-matched pediatric controls. Serum
levels of Gd-IgA1 were also elevated in a large fraction of
54 first-degree relatives of pediatric IgAN and HSPN patients
compared with 141 unrelated healthy adult controls.
A unilineal transmission of the trait was found in 17, bilineal
transmission in 1, and sporadic occurrence in 5 of 23 families
when both parents and the patient were analyzed. There was
a significant age-, gender-, and household-adjusted
heritability of serum galactose-deficient IgA1 estimated
at 76% in pediatric IgAN and at 64% in HSPN patients.
Thus, serum galactose-deficient IgA1 levels are highly
inherited in pediatric patients with IgAN and HSPN, providing
support for another shared pathogenic link between these
disorders.
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Immunoglobulin A nephropathy (IgAN) was first described
in 1968 (ref. 1) and is considered to be the most common
type of primary glomerulonephritis in the world.2 He-
noch–Scho¨nlein purpura (HSP) is the most frequent form of
vasculitis in children, with renal involvement in up to 40% of
cases.3 About 3% of children with HSP nephritis (HSPN)
progress to end-stage renal disease.4 The hypothesis that
IgAN and HSPN represent clinical phenotypes that share a
common pathogenic mechanism is strongly supported by
evidence from the indistinguishable renal immunohisto-
pathology5–7 and clinical observations.7–10 Genetic factors are
known to have an important role in susceptibility to IgAN,
and multiple extended pedigrees with familial forms of the
disorder have been reported worldwide.11–13 Interestingly,
patients with HSPN have been documented in several
pedigrees of related patients with IgAN.8,14 This observation
suggests that the same genetic factors that are involved in
IgAN may also operate in the pathogenesis of HSPN.
The pathogenetic entity shared by IgAN and HSPN is aberrant
glycosylation of O-linked glycans in the hinge region of a fraction
of IgA1 molecules.15–17 Rather than terminating with galactose,
the aberrant galactose-deficient O-glycans end with N-acetylga-
lactosamine (GalNAc) or sialylated GalNAc. The terminal
GalNAc moiety on the aberrantly glycosylated IgA1 may in turn
be recognized by antiglycan antibodies,18 leading to the formation
of nephritogenic circulating immune complexes that subse-
quently deposit in the glomerular mesangium to induce kidney
injury.19 Serum galactose-deficient IgA1 (Gd-IgA1) level is
elevated in patients with IgAN regardless of ethnicity or
age,20–24 and is also elevated in children with HSPN.21,25 Serum
Gd-IgA1 levels appear to be heritable in a dominant pattern in
IgAN, although most relatives with high levels have no clinical
manifestation of renal injury.26 Inheritance of high levels of
circulating Gd-IgA1 has recently been demonstrated in cohorts
of Caucasian, Asian, and African-American families with
IgAN.23,24,26 The purpose of this study was to determine whether
the serum levels of Gd-IgA1 in children with HSPN and IgAN are
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similarly heritable, providing further evidence for a shared
mechanism in the pathogenesis of the two diseases.
RESULTS
Baseline characteristics of patients
For the purpose of this study, we recruited 34 pediatric patients
with HSPN or IgAN, and their first-degree relatives (20 pediatric
cases of HSPN, 14 pediatric cases of IgAN, and 54 of their
relatives), as well as 51 healthy pediatric controls and 141 healthy
adult controls (Table 1). All participants were of Caucasian
ethnicity and were recruited from the same geographical region.
The clinical characteristics of the enrolled cases are summarized
in Table 2. All 14 cases of IgAN and 11 of 20 cases of HSPN were
diagnosed by renal biopsy. The remaining nine cases of HSPN
were diagnosed on the basis of clinical presentation (Supple-
mentary Table S1 online). The group of pediatric patients with
HSPN was slightly younger compared with children with IgAN
(mean age 10.1 versus 14.3 years, P¼ 0.002). However, there were
no statistically significant differences between the two case groups
in terms of gender, body mass index (BMI), blood pressure,
estimated glomerular filtration rate, microscopic hematuria, or
degree of proteinuria.
Serum total IgA and Gd-IgA1 levels increase with age in
healthy individuals
Circulating IgA levels have been reported to increase with
age, a pattern that may be attributable to the cumulative
number of mucosal antigenic exposures and/or the normal
immune aging process.27 In addition, previous studies noted
that serum Gd-IgA1 levels are lower in healthy children
compared with healthy adults.21,24,25 As serum total IgA and
Gd-IgA1 levels were highly correlated in this study, we first
explored the relationship with age for both measurements in
our cohorts (Figure 1). Total IgA and Gd-IgA1 levels were
significantly higher in the sera of adult controls compared
with pediatric controls (Po0.0001 for both traits). The levels
of total IgA and Gd-IgA1 also positively correlated with age
within the pediatric healthy control group (r¼ 0.42,
P¼ 0.002 for total IgA; r¼ 0.29, P¼ 0.04 for Gd-IgA1).
Among cases, however, older age was not associated with
higher levels, suggesting that the effect of age may be masked
by other factors with substantially larger effects in the affected
children. Considering a significant effect of age among
healthy subjects, we used a separate control group for adult
and pediatric patients.
Serum Gd-IgA1 level is a sensitive and specific biomarker of
pediatric HSPN and IgAN
Children with either IgAN or HSPN had significantly higher
serum Gd-IgA1 levels compared with pediatric healthy
controls (P¼ 1.7 107 and P¼ 6.5 109, respectively).
These differences were robust to additional adjustment for
age and gender (Figures 2c and d). No significant differences
in serum Gd-IgA1 levels were observed between children with
Table 1 | Summary of cohort characteristics
Pediatric IgAN, n=14 Pediatric HSPN, n=20 Pediatric controls, n=51
Age mean (±s.d.), yearsa 14.3 (±3.1) 10.1 (±3.9) 15.7 (±2.1)
Gender, M:F (%M) 10:4 (71) 13:7 (65) 28:23 (55)
Caucasian ethnicity (%) 14 (100) 20 (100) 51 (100)
BMI mean (±s.d.), kg/m2 23.8 (±6.7) 21.8 (±7.7) 21.7 (±7.3)
Total IgA mean (±s.d.), mg/ml 3.44 (±1.46) 3.02 (±1.17) 2.14 (±0.88)
Gd-IgA1 mean (±s.d.), U/ml 1250 (±630) 1130 (±490) 440 (±200)
495th percentile (%)b 8 (57) 12 (60) 2 (4)
490th percentile (%)c 12 (86) 13 (65) 5 (10)
475th percentile (%)d 14 (100) 20 (100) 12 (24)
Relatives of IgAN cases, n=25 Relatives of HSPN cases, n=29 Adult controls, n=141
Age mean (±s.d.), yearsa 43.0 (±6.2) 39.2 (±9.8) 36.6 (±13.3)
Gender, M:F (%M) 11:14 (44) 12:17 (41) 73:68 (52)
Caucasian ethnicity (%) 25 (100) 29 (100) 141 (100)
BMI mean (±s.d.), kg/m2 28.5 (±6.3) 29.5 (±6.5) 26.4 (±5.0)
Total IgA mean (±s.d.), mg/ml 2.95 (±1.34) 2.93 (±1.12) 2.91 (±1.21)
Gd-IgA1 mean (± s.d.), U/ml 1260 (±690) 1010 (±530) 700 (±310)
495th percentile (%)e 11 (44) 9 (31) 7 (5)
490th percentile (%)f 12 (48) 12 (41) 13 (9)
475th percentile (%)g 13 (52) 13 (45) 33 (23)
Abbreviations: BMI, body mass index; Gd-IgA1, galactose-deficient immunoglobulin A1; HSPN, Henoch–Scho¨nlein purpura nephritis; IgAN, IgA nephropathy.
aAge at the time of recruitment.
bNumber of individuals with Gd-IgA1495th percentile (970 U/ml).
cGd-IgA1490th percentile (780 U/ml).
dGd-IgA1475th percentile (380 U/ml) for healthy pediatric controls.
eNumber of individuals with Gd-IgA1495th percentile (1200U/ml).
fGd-IgA1490th percentile (1090 U/ml).
gGd-IgA1475th percentile (930 U/ml) for healthy adult controls.
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IgAN and children with HSPN (P¼ 0.50). In addition, these
differences were less pronounced for serum total IgA levels,
providing support for serum Gd-IgA1 as the better disease
biomarker. The sensitivity and specificity analysis of serum
Gd-IgA1 levels confirmed its superior predictive character-
istics compared with serum total IgA levels (Figures 2a and
b). In pediatric IgAN patients, the area under the receiver
operating characteristics (ROC) curve was estimated at 0.96
(95% confidence interval: 0.91–1.00) for Gd-IgA1 levels and
at 0.85 (95% confidence interval: 0.73–0.98) for total IgA
levels. In HSPN, the area for Gd-IgA1 was 0.94 (95%
confidence interval: 0.90–0.99) and for total IgA, it was 0.87
(95% confidence interval: 0.78–0.96). Additional adjustments
of serum measurements for age and gender did not
substantially alter the shape of the ROC curves.
Serum Gd-IgA1 level is inherited in pediatric HSPN and IgAN
Serum levels of Gd-IgA1 were elevated in the first-degree
relatives of pediatric IgAN and HSPN patients compared
with healthy adult controls (P¼ 3.2 106 and
P¼ 5.1 104, respectively; Figure 3a). In total, 11 of 25
(44%) relatives of IgAN patients and 9 of 29 (31%) relatives
of HSPN patients had levels above the 95th percentile
compared with healthy adult controls (Table 1). In addition,
the Gd-IgA1 levels did not differ between cases and their
relatives (P¼ 0.8 and P¼ 0.5, respectively; Figures 3b and c).
We also observed a strong positive correlation between
serum Gd-IgA1 levels for index cases and parents (r¼ 0.42,
P¼ 1.4 103; Figure 3d). When we stratified relatives on
the basis of the Gd-IgA1 level in the index cases, the relatives
of cases with high levels (above 95th percentile for pediatric
controls) had higher levels compared with relatives of index
cases with normal Gd-IgA1 levels (P¼ 0.042, Figure 3e).
Next, we analyzed the transmission of high serum Gd-IgA1
level in the 23 trios (both parents and the patient) available
for analysis. The unilineal transmission of the trait was
observed in 17 of 23 (B75%) families, bilineal transmission
in 1 (B5%) family, and sporadic occurrence in 5 (B20%)
families. This pattern is consistent with an autosomal
dominant inheritance with incomplete penetrance, but a
high sporadic rate is also apparent. We observed no
appreciable differences in the clinical characteristics of cases
with high versus low/normal Gd-IgA1 levels (Supplementary
Table S2 online).
Heritability of serum Gd-IgA1
Heritability was modeled using variance component meth-
ods.28 The distribution of Gd-IgA1 levels in families was
positively skewed, and required normalization by logarithmic
transformation before modeling (Supplementary Figure S1
online). The significant covariates in the polygenic models of
Gd-IgA1 included age (P¼ 0.016), sex (P¼ 0.038), and
household membership (P¼ 0.015). In the combined cohorts
of HSPN and IgAN, age and sex alone explainedB8% of the
variability, whereas household effects accounted for B5% of
the overall phenotypic variance in Gd-IgA1 levels. Collec-
tively, these covariates explained 14.4% of the trait’s variance
in the fully adjusted polygenic model. None of the pairwise
interaction terms between age, sex, or household member-
ship tested significant in the polygenic models. In the
combined cohorts, disease type (cohort membership) and
BMI (obesity) were not statistically significant. These
covariates and their interaction terms were subsequently
excluded from the final models.
The estimated heritability of the serum Gd-IgA1 level was
substantial and statistically significant in both cohorts
(Table 3). Age-, sex-, and household-adjusted heritability
was estimated at 63.7% (P¼ 0.018) in the HSPN cohort,
76.0% (P¼ 0.021) in the IgAN cohort, and 70.5%
(P¼ 0.0017) in both cohorts combined. In contrast to the
Gd-IgA1 levels, the unadjusted heritability of total IgA levels
was low and failed to reach statistical significance, even after
combining the cohorts (h2¼ 0.215, P¼ 0.17). Additional
adjustments for disease type, age, gender, BMI, and house-
hold effects did not improve this estimate (h2¼ 0.132,
P¼ 0.29). Moreover, addition of serum total IgA as a
covariate in the fully adjusted polygenic model of Gd-IgA1
did not substantially alter its heritability (h2¼ 0.685,
Table 2 | Clinical characteristics of pediatric patients with
IgAN and HSPN
Pediatric IgAN,
n=14
Pediatric HSPN,
n=20
Symptoms at presentation
Macroscopic hematuria (%) 12 (86) 7 (35)
Skin rash (%) 0 (0) 20 (100)
Joint symptoms (%) 0 (0) 11 (55)
Abdominal symptoms (%) 1 (7) 12 (60)
Diagnosis
Renal biopsy (%) 14 (100) 11 (55)
Clinical (%) 0 (0) 9 (45)
Clinical and laboratory data
Age at diagnosis (±s.d.), years 12.3 (±3.5) 7.0 (±2.0)
Male sex (%) 10 (71) 13 (65)
BMI (±s.d.), kg/m2 23.8 (±6.7) 21.8 (±7.7)
Normal BMI: o85th
percentile (%)
7 (50) 12 (60)
Overweight: 85th–95th
percentiles (%)
4 (29) 3 (15)
Obese: 495th percentile (%) 3 (21) 5 (25)
SBP (±s.d.), mmHg 118 (±16) 117 (±16)
DBP (± s.d.), mmHg 69 (±8) 67 (±8)
Serum creatinine mean (±s.d.),
mg/dl
1.0 (±0.7) 0.7 (±0.2)
eGFR mean (±s.d.), ml/min per
1.73m2
120 (±35) 116 (±28)
Microscopic hematuria (%) 12 (86) 15 (75)
Urinary protein/creatinine
ratio (g/g):
o0.15 (%) 1 (7) 3 (15)
0.15–0.29 (%) 4 (29) 4 (20)
0.30–3.00 (%) 8 (57) 12 (60)
43.0 (%) 1 (7) 1 (5)
Abbreviations: BMI, body mass index; DBP, diastolic pressure; eGFR, estimated glomerular
filtration rate; HSPN, Henoch–Scho¨nlein purpura nephritis; IgAN, immunoglobulin A
nephropathy; SBP, systolic pressure.
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P¼ 0.0017); thus, high heritability of the serum Gd-IgA1
level appears to be independent of any genetic factor that
may regulate serum total IgA level. Estimation of heritability
for age- and sex-adjusted BMI in our cohort (h2¼ 0.50,
P¼ 0.015) demonstrated values consistent with published
data in other cohorts,29–32 demonstrating a lack of bias in our
calculations.
DISCUSSION
This is the first study conducted to demonstrate that
circulating levels of Gd-IgA1 are highly heritable in children
with IgAN and HSPN. High heritability of Gd-IgA1 in our
cohort is consistent with three other family-based studies of
adult IgAN involving Caucasians,26 Asians,23 and, most
recently, African-Americans.24 Our data support a shared
inherited defect in the glycosylation of circulating IgA1 as a
central unifying link in the pathogenesis of IgAN and HSPN.
Similar to adult IgAN patients, we postulate that the
development of high levels of Gd-IgA1 is likely antecedent
to the disease process in children with IgAN and may
represent an inherited risk factor for nephritis because of
mesangial deposition of IgA1.13,33 However, we also note that
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Figure 1 | Serum total immunoglobulin A (IgA) and galactose-deficient IgA1 (Gd-IgA1) levels in pediatric cases, pediatric
controls, and adult controls. Correlations between (a) serum total IgA and Gd-IgA1; (b) age and serum total IgA; and (c) age and serum
Gd-IgA1. Pearson’s correlation coefficients with corresponding P-values are depicted above each graph. NS, not significant.
82 Kidney International (2011) 80, 79–87
or ig ina l a r t i c l e K Kiryluk et al.: Heritability of Gal-deficient IgA1
high Gd-IgA1 levels were observed in many asymptomatic
first-degree relatives of the affected children. Therefore, a
high serum Gd-IgA1 level is clearly not sufficient for the
development of clinical symptoms, and it is likely that a
‘second hit’ (that is, other environmental or inherited risk
factor) is required to produce overt disease.33 Recent studies
suggest that such a ‘second hit’ may be related to the
development of antiglycan antibodies that recognize the
galactose-deficient hinge-region O-glycans of IgA1 to form
nephritogenic immune complexes in patients with IgAN18 as
well as HSPN.34 In addition, we observed a smaller subgroup
of affected children with normal Gd-IgA1 levels (Supple-
mentary Table S2 online). This subgroup may represent a
disease category with distinct pathogenesis that is indepen-
dent of IgA1 glycosylation defects. Larger studies will be
required to better characterize this subgroup of patients.
In our study, serum Gd-IgA1 levels were similarly elevated
in children with IgAN or HSPN. In both disorders, the ROC
curve for the Gd-IgA1 level was superior compared with the
ROC curve for serum total IgA. These observations are
consistent with previous reports of detectable glycosylation
defects in patients with Henoch–Scho¨nlein purpura with
renal involvement.21,25 Furthermore, the area under the ROC
curve (AUC) for serum Gd-IgA1 appeared to be greater for
pediatric patients (AUC B0.94–0.96) when compared with
adults with IgAN (AUC B0.90).20 Although the age
adjustment did not significantly alter the ROC curves, the
effect of age on Gd-IgA1 levels in healthy pediatric controls
was statistically significant. Increasing levels of total IgA with
age in healthy children have been well described in literature;
total IgA concentration is lowest at birth and mean adult
levels are typically not reached until after puberty.35–37 The
effect of age on adult IgA levels is much less pronounced.27
Our data indicate that serum Gd-IgA1 levels appear to follow
a similar pattern in healthy children and adult controls.
Because of the correlation of Gd-IgA1 levels with age,
standardized age-specific normal ranges will likely need to be
developed for increased diagnostic utility of the serum test in
children. This study is not sufficiently powered to develop
such ranges, and larger studies of healthy pediatric popula-
tions will be required to develop age-normative data.
We also recognize several other limitations of our study.
Most importantly, the studied cohorts are relatively small and
limited to participants of Caucasian ancestry from a small
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Figure 2 | Serum galactose-deficient immunoglobulin A1 (Gd-IgA1) and total IgA levels as predictors of pediatric IgA nephropathy
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region of the United States. Despite the small sample size,
however, we achieved statistical significance of heritability
estimates, largely because of a substantial genetic component
to the variability in serum Gd-IgA1 levels. Additional
limitations stem from the method of heritability estimation
used in this study. Here, we examine the narrow sense
heritability of Gd-IgA1, defined as the proportion of
phenotypic variance explained by the additive genetic
component.38 This model ignores the effects of dominance,
epistasis, or gene–environment interactions, although these
effects are likely to cause only a downward bias in heritability
estimates.39 A more precise dissection of heritability could be
achieved in twin studies and more complete sets of larger
pedigrees, but such cohorts are not readily available for
pediatric IgAN or HSPN patients. Approximately 20% of
total variance in the serum Gd-IgA1 level could not be
explained by either the additive genetic component or
modeled confounders. This finding may be due to assay
variability, non-additive genetic effects, random fluctuations
of Gd-IgA1 levels, or other environmental/epigenetic factors.
Finally, we recognize that our heritability estimates are
strictly relative and population specific. Studies in cohorts of
diverse ethnic backgrounds and patients residing in different
geographic regions will be needed to establish the general-
izability of our findings.
We conclude that a serum Gd-IgA1 level is, in part,
genetically determined and may constitute a useful tool for
screening and stratification of pediatric patients at risk for
HSPN or IgAN. Age may represent an important confounder
in the studies of pediatric populations, and should be taken
into account in the interpretation of serum Gd-IgA1 levels.
Our findings of high heritability of Gd-IgA1 in pediatric
patients are consistent with previous studies involving adult
cases of IgAN.26 In aggregate, our observations highlight
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the potential clinical utility of Gd-IgA1 testing to identify
individuals at genetic risk of nephropathy. Additional studies
will be needed to determine whether a high serum Gd-IgA1
level correlates with any specific clinicopathological feature or
differential response to treatment. For this reason, we
strongly advocate for inclusion of serum Gd-IgA1 levels in
the evaluation and follow-up of patients in randomized
controlled trials for treatment of IgAN or HSPN. The
acquisition of prospective longitudinal data will help to
define the prognostic utility of this test. Finally, our data lay
a basis for future quantitative genetic mapping studies of
Gd-IgA1 aiming at the identification of specific gene(s)
responsible for this phenotype. Identification of genes and
pathways responsible for aberrant glycosylation of IgA1 may
ultimately lead to the development of novel therapeutic and
prophylactic approaches for these common childhood disorders.
MATERIALS AND METHODS
Study cohorts and clinical data
Our study included families recruited at the University of Tennessee
Health Sciences Center in Memphis. In total, we analyzed 33
Caucasian families (14 trios with pediatric IgAN, 18 trios with
pediatric HSPN, and 1 nuclear family with two siblings affected by
HSPN), as well as 51 age- and ethnicity-matched pediatric controls
and 141 healthy adult controls (Table 1). A single blood collection
from patients, their relatives, and healthy controls was performed for
the purpose of measurement of serum total IgA and Gd-IgA1. The
screening urine dipstick test was conducted in all study participants
at the time of recruitment. All healthy controls included in this
study had a negative urine test for blood and protein. Spot urine
protein and creatinine concentrations were measured in all cases,
and proteinuria was defined as a urinary protein/creatinine ratio
40.15 g/g. Estimated glomerular filtration rate was calculated using
the four-variable Modification of Diet in Renal Disease formula
for adults40 and the Schwartz formula for pediatric patients.41
We considered chronic kidney disease to be present in indivi-
duals with proteinuria or estimated glomerular filtration rate
o60ml/min/1.73m2. Microscopic hematuria was defined as
X1þ blood on urine dipstick test or 45 red blood cells per
high-power field on microscopic examination of the spun urinary
sediment. Macroscopic hematuria was defined by clinical history.
BMI was calculated as weight (kg)/height (m)2; obesity was defined
by BMI X30 kg/m2 in adults and above the 95th percentile for age-
and sex-matched healthy children of Caucasian ethnicity. Adults
with BMI 25–30 kg/m2 were considered overweight. Similarly,
children with BMI between the 85th and 95th percentiles for age-
and sex-matched healthy children were classified as overweight and
at risk for obesity, according to the guidelines of the American
Academy of Pediatrics.42 Consequently, we coded BMI as a
categorical variable with three levels (normal/overweight/obese)
for the purpose of polygenic modeling across family members of
varying age. All kidney biopsy diagnoses were confirmed by review
of the original pathology reports. The clinical (non-biopsy)
diagnosis of HSPN was defined by the presence of characteristic
purpuric skin lesions of HSP in combination with a heme-positive
dipstick test (X1þ ) and confirmed microscopic hematuria (45
red blood cells/high-power field). The clinical characteristics of the
enrolled patients are summarized in Table 2 and Supplementary
Table S1 online. All patients or their parents/guardians provided
written informed consent, and participants aged 8–18 years provided
written assent. The IRB committees at the participating institutions
approved the study protocol.
Measurement of serum total IgA levels
Serum levels of IgA were determined by capture enzyme-linked
immunosorbent assay (ELISA).20,43 ELISA plates were coated with
the F(ab0)2 fragment of goat IgG specific for human IgA (Jackson
ImmunoResearch, West Grove, PA) at 1mg/ml. The bound human
IgA was then detected with the F(ab0)2 fragment of goat IgG specific
for human IgA (Biosource, Camarillo, CA). The IgA concentration
Table 3 | Heritability estimates for serum Gd-IgA1 level in the HSPN, IgAN, and combined cohorts
Family cohort
Quantitative trait and covariate
adjustment
Proportion of variance
attributable to covariates (%)
Heritability
(P-value)*
Pediatric HSPN Crude Gd-IgA1 — 0.737 (P=9.4 103)
Age-adjusted Gd-IgA1 5.7 0.710 (P=1.4 102)
Sex-adjusted Gd-IgA1 9.8 0.685 (P=8.8 103)
Household-adjusted Gd-IgA1 4.9 0.686 (P=2.1 102)
Age- and sex-adjusted Gd-IgA1 18.7 0.690 (P=8.1 103)
Age-, sex-, and household-adjusted Gd-IgA1 22.3 0.637 (P=1.8 102)
Pediatric IgAN Crude Gd-IgA1 — 0.815 (P=1.0 102)
Age-adjusted Gd-IgA1 1.7 0.762 (P=2.2 102)
Sex-adjusted Gd-IgA1 0.5 0.814 (P=1.0 102)
Household-adjusted Gd-IgA1 1.9 0.804 (P=1.1 102)
Age- and sex-adjusted Gd-IgA1 2.1 0.770 (P=2.0 102)
Age-, sex-, and household-adjusted Gd-IgA1 4.1 0.760 (P=2.1 102)
Combined cohorts Crude Gd-IgA1 — 0.786 (P=3.7 104)
Age-adjusted Gd-IgA1 2.9 0.759 (P=8.1 104)
Sex-adjusted Gd-IgA1 4.1 0.770 (P=3.3 104)
Household-adjusted Gd-IgA1 5.0 0.747 (P=9.6 104)
Age- and sex-adjusted Gd-IgA1 7.9 0.764 (P=4.3 104)
Age-, sex-, and household-adjusted Gd-IgA1 14.4 0.705 (P=1.7 103)
Abbreviations: Gd-IgA1, galactose-deficient immunoglobulin A1; HSPN, Henoch–Scho¨nlein purpura nephritis; IgAN, IgA nephropathy.
The values of Gd-IgA1 levels were log-transformed and tested for deviations from normality before polygenic analysis. The Gd-IgA1 level was modeled with sequential
adjustment for age, sex, and household effects.
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was expressed in mg/ml, based on standard curves generated with
calibrated human IgA standards.
Measurements of serum Gd-IgA1
Measurements of serum Gd-IgA1 were taken using a lectin-based
ELISA, as previously described in detail.19 Briefly, the IgA levels
from samples and standard captured on ELISA plates were treated
with 1mU per well neuraminidase for 3 h at 37 1C. Samples were then
incubated with biotinylated GalNAc-specific lectin from Helix aspersa
(Sigma-Aldrich, St Louis, MO). The bound IgA1 was detected with
avidin–horseradish peroxidase conjugate, and the reaction was
developed with the peroxidase chromogenic substrate o-phenylene-
diamine–H2O2 (Sigma-Aldrich). The concentration of Gd-IgA1 was
calculated by interpolating the optical densities on calibration curves
constructed using neuraminidase-treated standard Gd-IgA1 myelo-
ma protein. The results were expressed in units/ml, where 1 unit of
Gd-IgA1 was defined as 1 mg of the standard Gd-IgA1 protein.
Statistical analysis
Summary statistics were calculated for demographic, clinical, and
biochemical characteristics, and expressed as proportions/percen-
tages for categorical data and means (±standard deviations) or
medians (ranges) for quantitative data. Pearson’s correlation
coefficients were used to explore relationships between quantitative
variables. Partial correlation coefficients were used to adjust for
selected covariates. Pairwise group comparisons were made using
two-sided Student’s t-test (or the Mann–Whitney U-test for non-
normally distributed data) and the w2-test for categorical data.
Multiple group comparisons in quantitative characteristics were
made using analysis of variance, or Wilcoxon’s rank-sum test for
non-normally distributed data. Two-tailed Po0.05 was considered
statistically significant. Multiple regression and ROC analyses were
performed in SPSS Statistics 17.0 (SPSS, Chicago, IL).
Polygenic modeling and heritability estimation
Before polygenic modeling, all traits were tested for normality by the
Shapiro–Wilk test and by visual examination of histograms and
quantile–quantile plots. All non-normal trait distributions were
normalized by logarithmic transformation (Supplementary Figure
S1 online). Summary statistics (mean, standard deviation, and
kurtosis) were derived for all transformed traits before and after
covariate adjustment. The covariates were screened by stepwise
selection in polygenic models of quantitative traits. The step criteria
consisted of covariate inclusion and exclusion P-value of 0.05
(the likelihood ratio test). Age, sex, and BMI, as well as all of their
first-order interaction terms, were tested for significance. We also
accounted for shared family environment by modeling household
effects. Polygenic analyses were performed using variance compo-
nents methods, as implemented in SOLAR version 2.1.2 (Texas
Biomedical Research Institute, San Antonio, TX).28,44 Heritability
estimates were derived assuming the additive genetic variance compo-
nent. Summary statistics, normality testing, transformations, and
linear regression analyses were performed with SPSS Statistics 17.0.
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